Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine

European Journal of Cancer

Volumn 32, Issue 5, 1996, Pages 821-825

  Frascella, E ^a   Pritchard Jones, K ^b   Modak, S ^b   Mancini, A F ^c   Carli, M ^a   Pinkerton, C R ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Carboplatin; Epirubicin; Rhabdomyosarcoma; Vincristine

Indexed keywords

CARBOPLATIN; EPIRUBICIN; VINCRISTINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; THROMBOCYTOPENIA;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; FEMALE; HUMANS; INFANT; MALE; RHABDOMYOSARCOMA; TREATMENT OUTCOME; VINCRISTINE;

EID: 0029995625     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00665-6     Document Type: Article

References (28)

1. Raney RB, Tefft M, Maurer H, et al. Disease patterns and survival rates in children with metastatic soft-tissue sarcoma. Cancer 1988, 62, 1257-1266.
2. Koscielnak E, Rodary C, Flamant F, et al. Metastatic rhabdomyosarcoma and histological similar tumors in childhood: a retrospective European multicenter analysis. Med Pediatr Oncol 1992, 20, 209-214.
3. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup rhabdomyosarcoma study-II. Cancer 1993, 71, 1904-1922.
4. Koscielnak E, Jürgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer 1992, 70, 2557-2567.
5. Pappo AS, Etcunabas E, Santana VM, et al. A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 1993, 71, 2119-2125.
6. Treuner J, Koscielnak E, Keik M, et al. Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother Pharmacol 1989, 24(s), S48-S50.
7. Flamant F, Rodary C, Rey P, et al. SIOP MMT 84 study: results on rhabdomyosarcoma with 4 years median follow up. Med Pediatr Oncol 1991, 19(s), 434.
8. Schmitt C, Flamant F, Rodary C. Efficiency of cisplatin-adriamycin in combination in children with rhabdomyosarcoma. Proc Am Soc Clin Oncol 1989, 8, 1194.
9. Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II trial of cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treat Rep 1981, 65, 815-822.
10. Carli M, Perilongo G, Cordero di Montezemolo L, et al. Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group. Cancer Treat Rep 1987, 71, 525-527.
11. Odone-Filho V, Maluf PT, Almeida MT, et al. Cisplatinum and VP16 as initial therapy for advanced rhabdomyosarcomas. Proc Am Soc Clin Oncol 1993, 12, 1423.
12. Philips M, Pinkerton CR. Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas. Eur J Cancer 1992, 28, 399-403.
13. Wang JJ, Holland JF, Sinks LF. Phase II study of Adriamycin in childhood solid tumors in children. Cancer Chemother Rep 1975, 6, 267-270.
14. Selawry OSD, Holland JF, Wolman IJ. Effect of vincristine on malignant solid tumors in children. Cancer Chemother Rep 1968, 52, 497-500.
15. Tan C, Rosen G, Ghavimi F, et al. Adriamycin in pediatric malignancy. Cancer Chemother Rep 1975, 6, 259-266.
16. Van Hoff DD. Whither carboplatin? A replacement for or an alternative to cisplatin? J Clin Oncol 1987, 5, 169-171.
17. Shen WP, Gillian E, Tishler D, Ewing NP, Weinthal J, Cairo M. A pilot study evaluating the toxicity and response rate of ifosfamide, carboplatin and etoposide (ICE) chemotherapy with G-CSF support for recurrent pediatric solid tumors. (Meeting abstract.) Proc Am Soc Clin Oncol 1993, 12, 1468.
18. Toma S, Palumbo R, Canavese G, et al. Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. Cancer Chemother Pharmacol 1993, 31(s), S222-S227.
19. Mott MG. Epirubicin in childhood malignancy. Adv Clin Oncol 1989, 2, 119-126.
20. Carli M, Pinkerton R, Frascella E, et al. Intensive chemotherapy for metastatic sarcoma in children. SIOP European Intergroup Study. Proc Am Soc Clin Oncol 1993, 410, 1404.
21. Carli M, Flamant F, Treuner J, Frascella E, Stevens M, Perilongo G. High dose epirubicin in combination with carboplatin and vincristine in stage IV childhood malignant mesenchymal tumors. Proc Am Soc Clin Oncol 1992, 11, 1272.
22. Raney RB Jr, Tefft M, Maurer HM, et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS) - 1. Cancer 1988, 62, 1257-1266.
23. Crist W, Gehan EA, Ragab AH, et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995, 12, 610-630.
24. Treuner J, Koscielniak E, Keim M. Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother Pharmacol 1989, 24(s), S48-S50.
25. Carli M, Pastore G, Perilongo P, et al. Tumour response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J Clin Oncol 1988, 6, 654-658.
26. Etcubanas E, Horowitz M, Vogel R. Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 1985, 69, 999-1000.
27. Pinkerton CR, Groot-Loonen J, Barrett A, et al. Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas. Br J Cancer 1991, 64, 381-385.
28. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993, 11, 15-21.